Gilead Sciences has discontinued the Phase III ENHANCE study of magrolimab, along with azacitidine, for the treatment of higher-risk myelodysplastic syndromes (MDS).

The double-blind, randomised study has been discontinued due to futility observed during a planned analysis.

Patients treated with the combined therapy showed typical adverse events and the safety data was consistent with the known magrolimab profile.

More than 500 patients were enrolled in the study and randomised to receive the combined therapy or azacitidine alone.

Overall survival and complete response were the primary endpoints while progression free survival and transfusion independence were included as the secondary endpoints.

The study also measured the duration of response and the time to transformation to acute myeloid leukaemia (AML) as secondary endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gilead Sciences chief medical officer Merdad Parsey said: “The health and well-being of patients are our top priorities and while this is disappointing news, it confirms the challenges of treating HR-MDS, where no new class of treatments have been approved in nearly 20 years.

“Gilead is deeply grateful to the patients, families, investigators, and the advocacy community who contributed to this research, as we learn more about magrolimab and explore its potential in treating other cancers.”

Working with the investigators, the company is taking suitable measures for the enrolled patients in the study.

Magrolimab is a monoclonal antibody that blocks the interaction of the CD47-signal regulatory protein (SIRPα) to destroy cancerous cells.

It is also being investigated in the ENHANCE-2 study to treat AML harboring TP53 mutations, in ENHANCE-3 as first-line treatment for unfit AML, and in other ongoing trials to treat solid tumours.